These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 19243239)

  • 1. Innate and adaptive immunity for the pathobiology of Parkinson's disease.
    Stone DK; Reynolds AD; Mosley RL; Gendelman HE
    Antioxid Redox Signal; 2009 Sep; 11(9):2151-66. PubMed ID: 19243239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease.
    Panaro MA; Cianciulli A
    Curr Pharm Des; 2012; 18(2):200-8. PubMed ID: 22229581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate and adaptive immune responses in Parkinson's disease.
    Schonhoff AM; Williams GP; Wallen ZD; Standaert DG; Harms AS
    Prog Brain Res; 2020; 252():169-216. PubMed ID: 32247364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on immunity and inflammation in Parkinson disease pathology.
    Joshi N; Singh S
    J Neurosci Res; 2018 Mar; 96(3):379-390. PubMed ID: 29072332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
    Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
    Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periphery and brain, innate and adaptive immunity in Parkinson's disease.
    Harms AS; Ferreira SA; Romero-Ramos M
    Acta Neuropathol; 2021 Apr; 141(4):527-545. PubMed ID: 33555429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat.
    Ambrosi G; Kustrimovic N; Siani F; Rasini E; Cerri S; Ghezzi C; Dicorato G; Caputo S; Marino F; Cosentino M; Blandini F
    Neurotox Res; 2017 Jul; 32(1):71-81. PubMed ID: 28285346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory response in Parkinson's disease (Review).
    Yan J; Fu Q; Cheng L; Zhai M; Wu W; Huang L; Du G
    Mol Med Rep; 2014 Nov; 10(5):2223-33. PubMed ID: 25215472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
    Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
    Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease.
    Chi Y; Fan Y; He L; Liu W; Wen X; Zhou S; Wang X; Zhang C; Kong H; Sonoda L; Tripathi P; Li CJ; Yu MS; Su C; Hu G
    Aging Cell; 2011 Jun; 10(3):368-82. PubMed ID: 21255222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological features of alpha-synuclein in Parkinson's disease.
    Roodveldt C; Christodoulou J; Dobson CM
    J Cell Mol Med; 2008 Oct; 12(5B):1820-9. PubMed ID: 18671754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages?
    Hopes L; Grolez G; Moreau C; Lopes R; Ryckewaert G; Carrière N; Auger F; Laloux C; Petrault M; Devedjian JC; Bordet R; Defebvre L; Jissendi P; Delmaire C; Devos D
    PLoS One; 2016; 11(4):e0147947. PubMed ID: 27035571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.
    Booij J; Berendse HW
    J Neurol Sci; 2011 Nov; 310(1-2):40-3. PubMed ID: 21840542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?
    Ziv I; Offen D; Barzilai A; Haviv R; Stein R; Zilkha-Falb R; Shirvan A; Melamed E
    J Neural Transm Suppl; 1997; 49():195-202. PubMed ID: 9266428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nigrostriatal interaction in the aging brain: new therapeutic target for Parkinson's disease.
    Błaszczyk JW
    Acta Neurobiol Exp (Wars); 2017; 77(1):106-112. PubMed ID: 28379221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
    Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
    Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease.
    Campos-Acuña J; Elgueta D; Pacheco R
    Front Immunol; 2019; 10():239. PubMed ID: 30828335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process?
    Ziv I; Barzilai A; Offen D; Nardi N; Melamed E
    J Neural Transm Suppl; 1997; 49():69-76. PubMed ID: 9266415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.